CHEK2 germline loss-of-function variants have been reported in certain pediatric cancer patient cohorts, including neuroblastomas, non-Hodgkin lymphomas, thyroid cancer, melanomas, sarcomas, and brain tumors. Here, CHEK2 is linked to brain neoplasm.